MIM
ENGN icon

Monashee Investment Management’s enGene Therapeutics ENGN Stock Holding History

Monashee Investment Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
320,000
+25,000
+8% +$223K 1.19% 30
2025
Q4 		$2.66M Buy
+295,000
New +$2.36M 1.5% 24

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Monashee Investment Management's ENGN Position: Q1 2026 in Review

Monashee Investment Management increased its enGene Therapeutics (ENGN) stake by 8.5% in Q1 2026, buying an estimated $223K and bringing the position to 320,000 shares worth $2.18M. The position accounts for 1.19% of the portfolio, ranked #30.

Monashee Investment Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.66M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Monashee Investment Management held 320,000 shares of enGene Therapeutics worth $2.18M as of Q1 2026.
  • Monashee Investment Management bought 25,000 enGene Therapeutics shares in Q1 2026, an estimated $223K.
  • enGene Therapeutics made up 1.19% of Monashee Investment Management's portfolio in Q1 2026, its #30 holding.
  • Monashee Investment Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Monashee Investment Management's enGene Therapeutics position peaked at $2.66M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Monashee Investment Management's 13F filing for Q1 2026, filed 13 May 2026.